FDA panel to scrutinize placebo in Amarin's Vascepa trial by Kyle Blankenship Tuesday, November 12, 2019 Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.
Amarin fends off supplement makers in fight over Vascepa CV data by Kyle Blankenship Wednesday, May 8, 2019 Aiming to protect Vascepa's CV advantage—and its fast-growing prescription count—Amarin's fighting supplement makers in court.
Amarin's Vascepa offers extended CV benefits by Angus Liu Monday, March 18, 2019 The fish oil-derived drug showed significant reduction not just in first cardiovascular events, but in recurrent incidence as well.
Believe it: Amarin's Vascepa delivers in big heart-risk study by Tracy Staton Monday, September 24, 2018 Call it a promise kept. Amarin has staunchly promised that Vascepa could prove it cuts heart risks, despite detractors' disbelief—and now it has.
JPM execs speak on 2018: Pricing moves, yes. M&A frenzy, no by Tracy Staton Monday, January 15, 2018 The J.P. Morgan Healthcare Conference was a great place to suss out the general biopharma mood as 2018 begins.
